BCL2L1 and neoplasm: Although preliminary studies in breast cancers demonstrate that inhibiting Bcl-2 or Bcl-2/Bcl-xL/Bcl-w in combination with targeted therapies is sufficient to dramatically increase tumor cell killing and survival, this might not be the case for all breast cancers, particularly those with MCL1-amplification.